Navigation Links
New breast cancer drug on the block

A new drug has been approved in Scotland for the treatment of breast cancers in the early stages. The drug named Arimidex seems to be beneficial // specifically in treating breast cancer in women, who have crossed menopause. Arimidex is an aromatase inhibitor that works by inhibiting the oestrogen production in the adrenal gland.

Apparently more than 4,000 women are expected to benefit from the use of this drug. England and Wales also intend to introduce this drug into the market by the end of this year. Keeping in mind the efficacy that has been noted so far, this drug is also due for consideration for the approval by National Institute of Clinical Excellence.

The medical journal Lancet has reported that this drug has helped in halving the risk of the illness relapsing in patients. Lancet Oncology reports that recipients of this drug have shown remarkable improvement after two to three years following surgery, as compared to the standard drug of choice, Tamoxifen. Their chances of succumbing to death on account of the cancer were reduced by 29%.The study reported in Lancet also shows that chances of relapse were minimized by 45% after introduction of this drug. The long term chance of occurrence of any other cancer in the lifetime of the patient also showed a considerable decline of 39% in the studies.

Professor Walter Jonat, the author of the study is confident that this drug will enable the breast cancer patients to face their future with confidence.
MST
'"/>




Page: 1

Related medicine news :

1. Ductal lavage may detect early breast cancer
2. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
3. Micro-camera provides new breast imaging technique
4. Support therapy helps breast cancer patients
5. Variation in breast cancer
6. Appropriate treatment for breast cancer
7. Combination therapy to treat breast cancer
8. Hope for breast cancer patients
9. Pregnancy weight linked to breast cancer
10. New breast cancer genes discovered
11. New breast cancer drug appears encouraging
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Mirror ... have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice ... named part of this elite group of providers. , Produced by Zeltiq, CoolSculpting ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, ... the fourth Cradle to Cradle Product Design Challenge , the Cradle to ... series of six circular design challenges scheduled to run through early 2018. The challenges ...
(Date:1/17/2017)... ... ... SC&H Group, a leading audit, tax, and consulting firm, announced that Chris ... practice . Rossi is the third technology consulting leader to join SC&H Group’s IT ... the practice continues to expand.     , Bringing more than 25 years of business consulting ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers Agency, a ... the latest beneficiary of their thriving community involvement program. The current campaign fundraises ... the dreams of terminally ill patients. Donations to this worthy cause may now ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Devices System Market 2016-2020" report to their offering. ... The global artificial pancreas ... the period 2016-2020. Global Artificial Pancreas Devices System Market ... inputs from industry experts. The report covers the market landscape and ...
(Date:1/17/2017)... , Jan. 17, 2017 The interventional ... billion by 2021 from USD 6.35 billion in 2016, ... driving the growth of this market are rising incidence ... for minimally invasive surgeries. The global interventional ... application, and region. On the basis of type, the ...
(Date:1/17/2017)... 2017 Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... in Q1 2017   ... Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical ... 23 rd at 8:30am Eastern Time to discuss the recent acquisition of ...
Breaking Medicine Technology: